Rhinostop 0.1% Dropper Bottle Nasal Drops 20 ml

Indications

Used for acute respiratory diseases with symptoms of rhinitis (runny nose), acute allergic rhinitis, eustachitis, hay fever, sinusitis, in cases of otitis media (as part of combination therapy to reduce swelling of the mucous membrane of the nasopharynx), to facilitate the performance of rhinoscopy.

Method of application and doses

Adults and children over 6 years old are administered 1-2 drops of 0.1% xylometazoline solution into each nasal passage 2-3 times a day.
Children aged 2 to 6 years use a 0.05% solution, 1-2 drops in each nasal passage 1-2 times a day.
Do not use the medication continuously for more than 3-5 days.

Section: Composition

Active ingredient: xylometazoline hydrochloride - 1.00 mg;
Excipients: disodium edetate dihydrate - 0.50 mg, sodium chloride - 9.00 mg, benzalkonium chloride, calculated as anhydrous substance - 0.15 mg, potassium dihydrogen phosphate - 3.63 mg, sodium phosphate dodecahydrate - 7.13 mg, purified water - up to 1 ml.

Contraindications

Increased sensitivity to xylometazoline, arterial hypertension, tachycardia, pronounced atherosclerosis, glaucoma, atrophic rhinitis, thyrotoxicosis, surgical interventions on the meninges (in history), conditions after transsphenoidal hypophysectomy, pregnancy, childhood (up to 2 years for 0.05% solution, up to 6 years for 0.1% solution).
Do not use during therapy with monoamine oxidase inhibitors and tricyclic antidepressants or tetracyclic antidepressants, including the 14-day period after their discontinuation, as well as with other medications that increase blood pressure.

With caution

Diabetes mellitus, ischemic heart disease (angina), prostatic hyperplasia, pheochromocytoma, porphyria, hyperthyroidism, breastfeeding period, patients with increased sensitivity to adrenergic drugs, accompanied by symptoms such as insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

Use during pregnancy and breastfeeding

The use of the drug is contraindicated during pregnancy. If the drug is necessary during lactation, breastfeeding should be discontinued. During breastfeeding, the drug may be used only if the expected benefit to the mother outweighs the potential risk to the child.

Special instructions

Before use, the nasal passages should be cleared.
It should not be used for an extended period, for example, in chronic rhinitis.
The recommended dose should not be exceeded, and the duration of treatment should not be increased.
Patients with long QT syndrome using xylometazoline may be at increased risk of developing serious ventricular arrhythmias.
Effect on the ability to drive vehicles and operate machinery
When the dosing regimen is followed, xylometazoline does not affect attention. At doses exceeding the recommended ones, the drug may affect the ability to drive vehicles or operate machinery.

Section: Side Effects

The frequency of side effects is assessed as follows:
very common: greater than or equal to 1/10;
common: greater than or equal to 1/100 and

Section: Overdose

Strengthening of side effects (dose-dependent), decrease in body temperature, confusion. The clinical picture of overdose may present as alternating phases of stimulation and suppression of the central nervous system and cardiovascular and respiratory systems. In case of accidental ingestion, the drug may cause: severe dizziness, increased sweating, headache, bradycardia, increased blood pressure, respiratory depression, coma, and seizures; after an increase in blood pressure, a sharp decrease may be observed.
Treatment: symptomatic.

Interaction

There may be an enhancement of systemic action when using monoamine oxidase inhibitors simultaneously with tricyclic antidepressants or tetracyclic antidepressants and adrenergic agents, therefore the simultaneous use of these medications is not recommended.

Section: Pharmacodynamics

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenergic activity, causing constriction of the blood vessels in the nasal mucosa, thereby eliminating edema and hyperemia of the nasal mucosa, restoring the patency of the nasal passages, and facilitating nasal breathing. The effect of the drug occurs within a few minutes after application and lasts up to 10 hours.

Section: Pharmacokinetics

When applied locally, the drug is practically not absorbed, therefore its concentration in the blood plasma is very low (not detectable by modern analytical methods).